Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4015 Target Snapshot

C-C chemokine receptor type 2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,314Compounds
423Assays
7Approved Drugs
5,278.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

C-C chemokine receptor type 2 shows late clinical disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P41597. Start with COVID-19, then reuse UniProt P41597 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with COVID-19, then reuse UniProt P41597 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
COVID-19

C-C chemokine receptor type 2 shows late clinical disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with COVID-19 because it currently carries late clinical support. Linked drugs include CENICRIVIROC. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats C-C chemokine receptor type 2 as ChEMBL target CHEMBL4015, mapped to UniProt P41597. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
C-C chemokine receptor type 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4015
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P41597
C-C chemokine receptor type 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether C-C chemokine receptor type 2 is the right protein anchor across sources, using UniProt P41597 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why COVID-19 is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameC-C chemokine receptor type 2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP41597
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelC-C chemokine receptor type 2
UniProt AccessionP41597
Component TypeProtein
Sequence Length374 aa

C-C chemokine receptor type 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as C-C chemokine receptor type 2, mapped to UniProt P41597. Sequence length is 374 aa.

Mapped IDP41597
Review nameC-C chemokine receptor type 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

C-C chemokine receptor type 2 shows late clinical disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugCENICRIVIROC
Late clinical Phase III
non-alcoholic fatty liver disease
1 linked drug · 1 direct · 1 efficacy
Linked drugCENICRIVIROC
Late clinical Phase III
non-alcoholic steatohepatitis
1 linked drug · 1 direct · 1 efficacy
Linked drugCENICRIVIROC
Clinical signal Phase II
diabetic nephropathy
4 linked drugs · 4 direct · 4 efficacy
Linked drugBMS-813160
Linked drugILACIRNON
Linked drugPF-04634817
Linked drugPLOZALIZUMAB
Clinical signal Phase II
neuropathic pain
2 linked drugs · 2 direct · 2 efficacy
Linked drugAZD2423
Linked drugBMS-741672
Clinical signal Phase II
pancreatic ductal adenocarcinoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugBMS-813160
Linked drugPF-4136309
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with COVID-19 because it currently carries late clinical support. Linked drugs include CENICRIVIROC. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseCOVID-19
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

7
Approved
3
Phase III
9
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC503,869.0
KI1,368.0
EC5019.0
KD22.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL41275 10.52 IC50 0.03 Preclinical
CHEMBL18442 10.4 IC50 0.04 Approved
CHEMBL2178578 10.0 Kd 0.1 Clinical
CHEMBL494191 10.0 IC50 0.1 Preclinical
CHEMBL3770912 9.89 IC50 0.13 Preclinical
CHEMBL230933 9.82 IC50 0.15 Preclinical
CHEMBL258205 9.7 IC50 0.2 Preclinical
CHEMBL3233186 9.7 IC50 0.2 Preclinical
CHEMBL3233188 9.7 IC50 0.2 Preclinical
CHEMBL502247 9.7 IC50 0.2 Preclinical
Distribution

pChEMBL Value Distribution

162
5.0
268
5.5
424
6.0
476
6.5
543
7.0
550
7.5
422
8.0
188
8.5
86
9.0
19
9.5
pChEMBL
Approved Drugs

Approved Drugs

PLERIXAFOR
CHEMBL18442
Approved 2008
Properties Compare Identifier
NIFEDIPINE
CHEMBL193
Approved 1981
Properties Compare Identifier
DISULFIRAM
CHEMBL964
Approved 1951
Properties Compare Identifier
Assay Landscape

Assay Landscape

423
Total Assays
1,943
Tested Compounds
2
Assay Types
Binding — 275 assays, 1,943 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 132 911 7.1
single protein format 121 736 7.2
cell membrane format 13 12 7.4
assay format 7 273 6.7
tissue-based format 2 11 8.4
Functional — 148 assays, 706 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 89 389 7.2
assay format 41 285 7.2
single protein format 7 1 7.8
tissue-based format 6 29 6.8
cell membrane format 5 2 7.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine